Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial

Journal:

The Lancet Oncology

Published:

2025-11-08

DOI:

10.1016/s1470-2045(25)00515-7

Affiliations:

21

Authors:

38

Go to article

Institutions	Authors	Share
State Key Laboratory of Oncology in South China, SYSUCC, China	11.500000 11.500000	0.30
SYSU-CAS Holdings United Laboratory of Frontier Radiotherapy Technology, China	6.500000	0.17
Affiliated Hospital of Guangdong Medical University, GDMU, China	2.000000	0.05
Tangdu Hospital, China	2.000000	0.05
Tongji Medical College, HUST, China	2.000000	0.05
Cancer Institute and Hospital, CAMS & PUMC, China	2.000000	0.05
Zhongshan City People's Hospital, China	2.000000	0.05
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.03
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China	1.000000	0.03
Tongji Hospital (TJH), HUST, China	1.000000	0.03
Fujian Cancer Hospital, China	1.000000	0.03
Fujian Medical University, China	1.000000	0.03
Cancer Hospital and Shenzhen Hospital, CAMS & PUMC, China	1.000000	0.03
The First Affiliated Hospital, SYSU, China	1.000000	0.03
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)	1.000000	0.03
Duke University Health System, United States of America (USA)	1.000000	0.03
Zhejiang Cancer Hospital (ZJCH), China	0.500000	0.01
Hangzhou Institute of Medicine (HIM), CAS, China	0.500000	0.01

Interested in Cardiovascular Medicine and Haematology?